ATI-1123 is a liposomal formulation of Taxotere.

The NCI selected Azaya Therapeutics’ lead cancer therapy, ATI-1123, for further investigation. The institute will conduct ADMET studies to help the company file an IND.


ATI-1123 is an advanced liposomal formulation of Taxotere. NCI’s Nanotechnology Characterization Laboratory (NCL) will conduct and fund the in vitro and in vivo studies on this molecule.


The agreement is part of the NCI’s Alliance for Nanotechnology in Cancer. The NCL reports that it has developed a series of protocols that produce a characterization profile for many different kinds of nanoparticles with potential medical applications. These profiles include information on size, morphology, purity, chemical composition, and stability.

Previous articleTgen and Applied Biosystems Use SOLiD 3 System for Genomic Research
Next articleAstraZeneca to Continue Collaboration with Dynavax until July 2010